Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb24306 + Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT05243342Phase 1Completed
- Sponsor
- Genentech
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, open-label trial of efbalropendekin alfa in multiple myeloma (MM) (2 arms), sponsored by Genentech. Primary endpoint: Percentage of participants with adverse events up to 3 years. Started Apr 2022; status: completed.
02
Drugs
efbalropendekin alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05243342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243342.